

## South West London Formulary

The Formulary details medicines recommended to be prescribed for mental health, OCD, eating disorders, learning disability & substance misuse across South West London, and should be read in conjunction with the relevant shared care guidance. Dressings and nutritional products relate to inpatient use only.

### Recommendations:

- SWLSTG community doctors should prescribe only psychotropic medicines.
- Inpatient doctors should also refer to acute Trust Formularies for physical health medicines and anti-infectives.
- [St George's NHS Trust formulary](#)
- [Epsom & St Helier NHS Trust formulary](#)
- [Kingston Hospital formulary](#)
- Follow Wandsworth CCG formulary for nicotine replacement products (includes bupropion and varenicline).
- Be familiar with NHS England guidance on self-limiting conditions that do not require treatment or can be treated with over the counter medicines from a pharmacy and help patients to self-care for these conditions where appropriate. [Click here for Quick Reference Guide](#)
- Contact Medicines Information 020 3513 6829 or [medinfo@swlstg.nhs.uk](mailto:medinfo@swlstg.nhs.uk) for help and advice.
- Prescribing guidance for primary care is available on the Trust [website](#), see [BNF](#), [BNFc](#) and [Manufacturer's SmPC](#) for full details.
- Where medicines are included in the formulary, they are approved for their licensed indications and may be prescribed in secondary or primary care EXCEPT hospital-only medicines (**amber shading**)
- For 'off-label' indications below (last column): **Green** are **approved 'off-label' indications that may be transferred to GPs**, **Amber** 'off-label' indications are **approved for use in the Trust but may NOT be transferred to GPs** and **Red** indications **CANNOT be prescribed at all**. Indications are [hyperlinked](#) to national guidance or referenced at the end of the document.

Non-formulary medicines:	Changes since April '19		
	Added:	Removed:	Amended:
Agomelatine Asenapine Duloxetine Loxapine inhalation Lurasidone Olanzapine pamoate Oxazepam Paliperidone (oral) Citalopram drops			Some off-label indications in line with update of the Trust formulary policy

Medicine	Formulations	Restrictions	Additional/off label information
<b>3.4.1 Sedating antihistamines</b>			
Promethazine	tablet 10mg, 25mg liquid 5mg / 5ml injection 25mg/mL		<a href="#"><i>Aggression / disturbed behaviour / rapid tranquillisation</i></a>
4.1 Hypnotics & Anxiolytics		See Prescribing for dependence policy	
<b>4.1.1 Hypnotics</b>			
Nitrazepam	tablet 5mg, liquid 2.5mg / 5ml	Use with caution & at lower dosage in the elderly (see BNF)	
Zopiclone	tablet 3.75mg tablet 7.5mg	*1 <sup>st</sup> line	<a href="#"><i>NICE TA77</i></a>
Zolpidem	tablet 5mg tablet 10mg	*2 <sup>nd</sup> line after zopiclone	<a href="#"><i>NICE TA77</i></a>
Melatonin	tablets 2mg MR (Circadin <sup>®</sup> )	See shared care	Short-term use for insomnia in children and adolescents in neurodevelopmental disorders <sup>i</sup>
<b>4.1.2 Anxiolytics</b>			<a href="#"><i>Agitation in acute phase of mania<sup>ii</sup></i></a> <a href="#"><i>Aggression / disturbed behaviour / rapid tranquillisation</i></a> <a href="#"><i>3<sup>rd</sup> line akathisia<sup>iii</sup> (short term)</i></a>
Diazepam	tablet 2mg, 5mg, 10mg. liquid 2mg/5ml, 5mg/5ml. injection emulsion 5mg/ml, rectal solution 5mg, 10mg	Injection <u>intravenous</u> (IV) only	
Chlordiazepoxide	capsule 5mg, 10mg	2 <sup>nd</sup> line	<a href="#"><i>for alcohol detoxification only</i></a>
Lorazepam	tablet 1mg, 2.5mg injection: 4mg /1ml.	IM gluteal, or deltoid when safe/trained 4mg/1ml injection: dilute 1:1 with water for injection / sodium chloride 0.9%	

Medicine	Formulations	Restrictions	Additional/off label information
<b>4.2 Medicines used in psychoses and related disorders</b> <b>4.2.1 Antipsychotic Medicines</b>		See Treatment with antipsychotics policy	<i>Aggression / disturbed behaviour / rapid tranquillisation</i> High dose (above BNF maximum aggregate dose) prescribing for psychosis <sup>iv</sup> <i>Emotionally unstable personality disorder short term low dose</i> Organic brain disease <i>Augmentation in OCD and BDD low dose (4th line)</i> <i>Dementia in those at risk of harming themselves or others and/or experiencing agitation, hallucinations or delusions causing them severe distress</i>
<b>Typical Antipsychotics</b>			
Chlorpromazine	tablet 10mg, 25mg, 50mg, 100mg liquid 25mg/5ml, 100mg/5ml		
Flupentixol dihydrochloride	3mg tablet		
Haloperidol	capsule 500 microgram, tablet 1.5mg, 5mg, 10mg liquid 5mg/5ml, 10mg/5ml injection 5mg/1ml	1st line, oral or parenteral Pre-treatment ECG required	<i>Delirium</i>
Sulpiride	tablet 200mg, 400mg liquid 200mg / 5ml	200mg tablets 1 <sup>st</sup> line	
Trifluoperazine	tablet 1mg, 5mg** liquid 5mg/5ml	**Manufacturing delays frequent consider switching to another medicine.	
Zuclopenthixol acetate (“Clopixol Acuphase <sup>®</sup> ”)	injection 50mg, 100mg		
Zuclopenthixol dihydrochloride	tablet 2mg, 10mg, 25mg		
<b>Atypical Antipsychotics</b>		<i>Augmentation in depression where initial treatment has failed</i> <i>Aggression following head trauma<sup>v</sup></i>	
Amisulpride	tablet 50mg, 200mg, 400mg liquid 100mg / 1ml		Psychosis <sup>iv</sup>
Aripiprazole	tablet 5mg, 10mg, 15mg orodisp tab. 10mg, 15mg injection 7.5mg in 1ml Oral liquid	*Not 1st line for any indication Max 15mg/day in schizophrenia Use liquid only if doses are <2.5mg/day	NICE <a href="#">TA213</a> , <a href="#">TA292</a> Psychosis <sup>iv</sup> Antipsychotic-induced hyperprolactinaemia <sup>vi</sup>

Medicine	Formulations	Restrictions	Additional/off label information
Clozapine	tablet 25mg, 100mg (Zaponex) liquid 50mg/mL (Denzapine) solution 50mg/ml (Zaponex St George's, special)	See Clozapine Guide	Psychosis not otherwise specified, with agreement from the current clozapine monitoring service <sup>iv</sup>
Olanzapine	tablet 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg dispers. tablet 5mg, 10mg, 15mg  injection 10mg unlicensed for rapid tranquilisation	Orodispersible for dysphagia or supervised administration only. 2nd line in delirium (oral only), where ECG monitoring is unavailable or impractical, previous dystonic or poor therapeutic reaction to haloperidol	<u>Prevention of moderate or severe bipolar depression</u> Psychosis <sup>iv</sup> Initiated on the advice of specialist eating disorder services for OCD and anxiety associated with anorexia nervosa in adults after psychological/ behavioural interventions have failed <sup>vii</sup>
Quetiapine	tablet 25mg, 100mg, 150mg, 200mg, 300mg	<u>twice</u> daily dosing	Psychosis <sup>iv</sup> Generalised anxiety disorder <sup>viii</sup>
	M/R tablet 50mg, 200mg, 300mg, 400mg	For supervised administration or patient preference only	
Risperidone (oral)	tablet 500microg, 1mg, 2mg, 3mg, 4mg, 6mg dispers. tablet 1mg, 2mg, 3mg, 4mg. liquid 1mg / 1ml	1 <sup>st</sup> line* Optimum oral dosage 4-6mg per day in schizophrenia. Orodispersible for dysphagia or supervised administration only	
<b>4.2.2. Antipsychotic Depot Injections</b>			
Aripiprazole	300mg, 400mg injection	Complete initiation form before prescribing and send to pharmacy for approval.	
Flupentixol decanoate	20mg/1ml, 40mg/2ml, 50mg/0.5ml, 100mg/1ml, 200mg/1ml.		
Fluphenazine decanoate	12.5mg/0.5ml, 25mg/1ml, 50mg/0.5ml & 100mg/1ml	Discontinued	
Haloperidol decanoate	50mg/1ml, 100mg/1ml		
Pipotiazine palmitate	50mg/1ml, 100mg/2ml	Discontinued	
Zuclopenthixol decanoate	200mg/1ml, 500mg/1ml		
Paliperidone monthly and 3 monthly	All strengths.	Complete initiation form before prescribing and send to pharmacy for approval.	Gluteal administration for loading doses (inpatients only, time to steady state blood levels prolonged) <sup>ix</sup>

Medicine	Formulations	Restrictions	Additional/off label information
<b>4.2.3 Anti-manic Medicines</b>			
Carbamazepine	See Antiepileptic Medicines		
Lamotrigine			
Sodium valproate			
Lithium carbonate	“Priadel” tablet MR 200mg, 400mg	See Shared care & prescribing policy	
Lithium citrate	Liquid 10.8mmol Li / 5ml (“Li-liquid”)	10.8mmol/5ml = 400mg lithium carbonate	
Semisodium valproate “Depakote”	tablet e/c 250mg, 500mg	2nd line valproate preparation	Should not be used during pregnancy and in women of child-bearing potential unless clearly necessary i.e. in situations where other treatments are ineffective or not tolerated and Pregnancy Prevention Programme criteria met.
Medicine	Formulations	Restrictions	Additional/off label information
<b>4.3 Antidepressant Medicines</b>		See Depression and Anxiety prescribing policy	
<b>4.3.1 Tricyclic &amp; related antidepressant Medicines</b>			
Amitriptyline	tablet 10mg, 25mg, 50mg liquid 50mg / 5ml		
Clomipramine	caps 10mg, 25mg, 50mg		<u>2<sup>nd</sup> line option for panic disorder</u>
Imipramine	tablet 10mg, 25mg, liquid 25mg/5ml		<u>2<sup>nd</sup> line option for panic disorder</u>
Lofepramine	tablet 70mg, liquid 70mg / 5ml		
Nortriptyline	tablet 10mg, 25mg		
Trazodone	capsule 50mg, 100mg, liquid 50mg/5ml	Not first-line treatment	
<b>4.3.2 Monoamine – oxidase inhibitors (MAOIs)</b>			
☞ Phenzazine	tablet 15mg	Not first-line treatment	
☞ Isocarboxazid	tablet 10mg	Not first-line treatment	
☞ Tranylcypromine	tablet 10mg	Not first-line treatment	
<b>Reversible MAOIs</b>			
Moclobemide	tablet 150mg	Not first-line treatment	

Medicine	Formulations	Restrictions	Additional/off label information
<b>4.3.3 Selective serotonin re-uptake inhibitors</b>	<u>Post Traumatic Stress Disorder (Off-label - fluoxetine, citalopram and escitalopram)</u> <u>Generalised anxiety disorder (GAD) (Off-label - sertraline, fluoxetine, citalopram)</u> National OCD/BDD service (consultants) recommendation only <sup>x</sup> : Sertraline up to 400mg/day, citalopram up to 60mg/day & fluoxetine up to 120mg/day. Plasma level and ECG prior to increasing above BNF maximum, and once target dose reached, then annual ECG.		
Citalopram	tablet 10mg, 20mg		Baseline ECG to exclude QTc prolongation. Monitor ECG & other risk factors when prescribed in conjunction with other medicines likely to prolong QTc interval <sup>xi</sup> <u>CAMHS initiation 2nd line treatment options after fluoxetine for depression and anxiety disorders in children over the age of 12 years old in line with NICE &amp; local guidance</u>
Fluoxetine	capsule 20mg liquid 20mg/5ml dispersible tablet 20mg	1 <sup>st</sup> line antidepressant	<u>Prevention and management of moderate or severe bipolar depression</u> £ Note : the most cost effective formula for people with swallowing difficulties is dispersible tablets unless the dose is not a 20mg increment where oral solution should be used – S/F oral solution should not be used.
Paroxetine	tablet 20mg, 30mg, liquid 10mg/5ml		
Sertraline	tablet 50mg, 100mg	1 <sup>st</sup> line antidepressant 1 <sup>st</sup> line anxiety	<u>CAMHS initiation 2nd line treatment options after fluoxetine for depression and anxiety disorders in children over the age of 12 years old in line with NICE &amp; local guidance</u>
Escitalopram	Tablet 5mg, 10mg, 20mg	2nd Line antidepressant	<u>Baseline ECG to exclude QTc prolongation. Monitor ECG &amp; other risk factors when prescribed in conjunction with other medicines likely to prolong QTc intervalxii</u>
<b>4.3.4 Other antidepressant Medicines</b>			
Mirtazapine	Tablet 15mg, 30mg, 45mg orodispersible tablet 15mg, 30mg, 45mg	Not first-line treatment	2 <sup>nd</sup> line for akathisia (low dose) <sup>iii</sup>
Venlafaxine	tablet 37.5mg, 75mg MR caps 75mg, 150mg. Vensir XL when on FP10.	Immediate release 1 <sup>st</sup> line preparation MR only where the patient prefers.	<u>GAD, Social Anxiety Disorder (SAD) and panic disorder</u> <u>PTSD in adults (75-300mg/day)</u>
Vortioxetine	Tablet 5mg, 10mg, 20mg	Inadequate response to two antidepressants within current episode of depression in adults.	NICE <a href="#">TA367</a>

Medicine	Formulations	Restrictions	Additional/off label information
<b>4.4 Central Nervous System Stimulants &amp; attention deficit hyperactivity disorder</b>			See Shared care & NICE <a href="#">TA98</a>
Atomoxetine	capsule 10mg, 18mg, 25mg, 40mg, 60mg	*2nd line (1 <sup>st</sup> line where substance misuse issues, risk of diversion or anxiety issues) Shared care Specialist ADHD prescriber initiation only	
Dexamfetamine sulphate	tablet 5mg	*3 <sup>rd</sup> line Shared care Specialist ADHD prescriber initiation only	<a href="#">Adult ADHD</a>
Lisdexamfetamine	capsules 30mg, 50mg, 70mg	*2 <sup>nd</sup> line (1 <sup>st</sup> line where substance misuse issues, risk of diversion or anxiety issues) Shared care Specialist ADHD prescriber initiation only	
Methylphenidate hydrochloride	tablet 5mg, 10mg	Shared care Specialist ADHD prescriber initiation only	<a href="#">Adult ADHD</a>
Methylphenidate hydrochloride	Xenidate, Equasym & Medikinet XL  <b>Concerta - where Xenidate XL cannot be used due to tolerability</b>	*1 <sup>st</sup> line Xenidate XL Shared care. Specialist ADHD prescriber initiation only	<a href="#">ADHD in children under 6 years of age (but not less than 4 years)</a> Consultant CAMHS - Doses up to 108mg for Xenidate XL, Doses up to 100mg for Equasym-XL and Medikinet XL <sup>xiii</sup> <a href="#">Adult ADHD</a>
Guanfacine	Tablet 1mg, 2mg, 3mg & 4mg	*2nd line (1 <sup>st</sup> line where substance misuse issues, risk of diversion or anxiety issues) Shared care Specialist ADHD prescriber initiation only	

Medicine	Formulations	Restrictions	Additional/off label information
<b>4.8 Antiepileptics (treatment / prevention of psychiatric symptoms)</b>			
Carbamazepine	tablet 100mg, 200mg, 400mg tablet MR 200mg, 400mg liquid 100mg / 5ml	Low dose	Aggressive, agitated and disturbed behaviour in dementia <sup>xiv</sup>
Clonazepam	tablet 500 microgram, 2mg		Acute mania <sup>ii</sup> <u>Aggression / disturbed behaviour / rapid tranquillisation</u> Akathisia <sup>iii</sup>
Lamotrigine	tablet 25mg, 50mg, 100mg, 200mg dispers. tab. 5mg, 25mg, 100mg		Augmentation in treatment resistant schizophrenia <sup>iv</sup> <u>Prevention of moderate or severe bipolar depression</u> Prevention of Clozapine-induced seizures <sup>iv</sup>
Pregabalin	Capsules 25mg, 100mg, 300mg	3 <sup>rd</sup> line as per NICE for GAD	Initiation form to be completed. Must be prescribed twice daily.
Sodium valproate	tablet 100mg, 200mg, 500mg tablet MR 200mg, 300mg, 500mg liquid 200mg / 5ml	1 <sup>st</sup> line valproate preparation for affective disorders 'E/c'	Should not be used during pregnancy and in women of child-bearing potential unless clearly necessary i.e. in situations where other treatments are ineffective or not tolerated and Pregnancy Prevention Programme criteria met. <u>Bipolar disorder</u> Prevention of Clozapine-induced seizures <sup>iv</sup> Impulsive or repetitive aggression in adults <sup>xv</sup>



Medicine	Formulations	Restrictions	Additional/off label information
<b>4.9 Medicines used in parkinsonism and related disorders</b>			
<b>4.9.2 Antimuscarinic Medicines used in parkinsonism</b>			
Procyclidine	tablet 5mg, liquid 5mg/5ml injection 5mg/1ml		
Trihexyphenidyl (Benzhexol)	tablet 2mg, 5mg		
<b>4.10 Medicines used in substance dependence</b>			
<b>Alcohol dependence</b>			
Acamprosate	tablet 333mg	Initiation by Addictions only	Patient must be engaged with a form of psychosocial support NICE <a href="#">TA325</a>
Disulfiram	tablet 200mg	Initiation by Addictions only	
Naltrexone	tablet 50mg	Initiation by Addictions only	
Nalmefene	tablet 18mg	May be initiated by GPs only.	Psychosocial support needed with treatment.
<b>Opioid dependence</b>		Initiation by Addictions only	NICE <a href="#">TA114</a>
Buprenorphine	tablet sublingual 8mg, 2mg & 400microgram		
Buprenorphine/naloxone	tablets 2mg/500microrams, 8mg/2mg	Initiation by Addictions only	Substitution treatment for opioid dependence in the framework of medical psychological and social treatment for patients over 15 yrs who have agreed to treatment. Those with a history crushing and injecting tablets Those known to divert prescribed medication Those unable to comply with supervised consumption of buprenorphine in first 3 months of treatment due to work or child care commitments or physical disability Those transferred from another service already initiated on Suboxone®.

Medicine	Formulations	Restrictions	Additional/off label information
Lofexidine	tablet 200 micrograms		
Methadone	liquid "mixture" 1mg /1ml (sugar free)		
Methadone	Tablet 5mg	For overseas travel only	
Naltrexone	tablet 50mg		NICE <a href="#">TA115</a>
Naloxone	2mg/2mL pre-filled syringe	Addictions teams only	See Naloxone To Take Home Appendix 10 in Prescribing for Dependence Policy
<b>4.11 Medicines for dementia</b>			See shared/transfer of care NICE <a href="#">TA217</a> <a href="#">Dementia in Parkinson's disease</a> <a href="#">Dementia with Lewy Bodies</a>
Donepezil	tablet 5mg, 10mg orodisp tablet 5mg, 10mg	1 <sup>st</sup> Line	
Galantamine	Capsules MR, 8mg, 16mg, 24mg Tablet 8mg, 12mg	1 <sup>st</sup> line MR preparation	
Rivastigmine	capsule 1.5mg, 3mg liquid 2mg / 1ml patch 4.6mg/24hours, 9.5mg/24hours, 13.3mg/24hours		£ Note : For doses above 3mg it is more cost effective to use a combination of 1.5 and 3mg capsules rather than the 4.5 or 6mg capsule.
Memantine	Tablet/orodispersible 10mg, 20mg Liquid 5mg/pump		
<b>9.6.7 Multivitamin preparations</b>			
Valupak multivitamins and minerals	tablet	Eating disorders inpatient service only	Adjunct in emergency diet in patients at risk of re-feeding syndrome
Thiamine	tablet		In line with prescribing for dependency policy
Vitamin B Co Strong	tablet		In line with prescribing for dependency policy
<b>1.3.2 Selective antimuscarinics</b>			
Hyoscine	hydrobromide tablet 300 micrograms transdermal patch 1.5mg	1st line	<a href="#">Clozapine induced hypersalivation<sup>iii</sup></a>
Pirenzepine	tablet 50mg	2 <sup>nd</sup> line	<a href="#">Clozapine induced hypersalivation<sup>iii</sup></a>
Atropine	1% eyedrops (sublingually)	3 <sup>rd</sup> line	<a href="#">Clozapine induced hypersalivation<sup>iii</sup></a>

Medicine	Formulations	Restrictions	Additional/off label information
<b>Other</b>			
Propranolol			2 <sup>nd</sup> line for akathisia (low dose) <sup>iii</sup>
Amantadine			Antipsychotic-induced hyperprolactinaemia <sup>vi</sup>
Bromocriptine			Antipsychotic-induced hyperprolactinaemia <sup>vi</sup>
Low dose antipsychotics, mood stabilisers, antidepressants, beta-blockers, sedating antihistamines or benzodiazepines			<u>Autistic Spectrum Disorders which can be associated with comorbid psychopathology including: over-arousal, hyperactivity, rage outbursts, anxiety, Tourette-type complex tics, OCD, mood disturbance, paranoia or sleep disturbance.</u>
Metformin			<u>Antipsychotic-induced weight gain after non-pharmacological interventions fail</u>
Phosphodiesterase-5 (PDE-5) inhibitors (sildenafil)			Antipsychotic induced erectile dysfunction that causes severe distress <sup>xvi</sup> after thorough assessment <sup>xvii,xviii,xix</sup> and review by a specialist or GP

**Nutritional feeds used by the inpatient mental health service only:**

Tube feeds:

Nutrison Standard 1.0 kcal/ml  
 Nutrison Energy 1.5k kcal/ml  
 Nutrison Multifibre 1.0 kcal/ml  
 Nutrison Energy Multifibre 1.5 kcal/ml.

Fortisip Multi Fibre  
 Fortisip Compact  
 Fortisip Compact Fibre  
 Fortimel  
 Fortisip Yoghurt Style  
 Fortisip Savoury Multi Fibre  
 Fortijuice  
 Calogen  
 Calogen Extra shot

Forticreme Complete  
 Fortisip Fruit Dessert  
 Complian Shake

Thickener/thickened products  
 Nutilis clear  
 Nutilis Complete

Oral Nutrition Support products

Skandishake  
 Fortisip

Complan

**Wound care products-** see the wound care product supply poster.

For further information on formulary decisions please contact Medicines Information on [MedInfo@swlstg.nhs.uk](mailto:MedInfo@swlstg.nhs.uk).

## References

---

- <sup>i</sup> [NICE Evidence Summary Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin ESUOM2 Jan 2013](#)
- <sup>ii</sup> [F Curtin & P Schulz 2004](#)
- <sup>iii</sup> [Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010 Feb;196\(2\):89-91](#)
- <sup>iv</sup> The Maudsley Prescribing Guidelines 12th Edition (2015); Taylor, Paton and Kapur; Wiley Blackwell.
- <sup>v</sup> [EP Elovic et al., 2003](#)
- <sup>vi</sup> [Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin \[Internet\]. 2016;6\(4\):185-90](#)
- <sup>vii</sup> [Dunican KC et al. The Role of Olanzapine in the treatment of anorexia nervosa 2007, Attia E, Kaplan A, Walsh B, Gershkovich M, Yilmaz Z, Musante D et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychological Medicine. 2011; 41\(10\):2177-2182.](#)
- <sup>viii</sup> [https://www.cochrane.org/CD008120/DEPRESSN\\_second-generation-antipsychotic-drugs-for-anxiety-disorders](https://www.cochrane.org/CD008120/DEPRESSN_second-generation-antipsychotic-drugs-for-anxiety-disorders)
- <sup>ix</sup> Company communication on file
- <sup>x</sup> [Ninan PT, Koran LM, Kiev A, et al. \(2006\) High-dose sertraline strategy for non-responders to acute treatment for obsessive-compulsive disorder: A multicentre double-blind trial. J Clin Psychiatry 67: 15–22, Pampaloni I et al. \(2010\) High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. J Psychopharmacol 24: 1439–1445](#)
- <sup>xi</sup> [Citalopram SPC May-19](#)
- <sup>xii</sup> [Escitalopram SPC Apr-18](#)
- <sup>xiii</sup> [BAP Evidence-based guidelines for the pharmacological treatment of ADHD 2014, Banaschewski T. et al 2006](#)
- <sup>xiv</sup> [Davies et al 2018](#)
- <sup>xv</sup> [Jones, RM et al. 2011](#)
- <sup>xvi</sup> [Health Service Circular 1999/177. Treatment for impotence: patients with severe distress.](#)
- <sup>xvii</sup> BSSM. British Society for Sexual Medicines Guidelines on the Management of Erectile Dysfunction. <http://bssm.org.uk/resources/>
- <sup>xviii</sup> NHS Clinical Knowledge Summaries (CKS). Clinical Topics – Erectile Dysfunction. <https://cks.nice.org.uk/erectile-dysfunction>
- <sup>xix</sup> BSSM. Society for Sexual Medicines Guidelines on the Management of Erectile Dysfunction. Accessed online at [www.bssm.org.uk](http://www.bssm.org.uk)